Abstract

The COVID-19 pandemic caused by SARS-CoV-2 is a continuous challenge worldwide, and there is an urgent need to map the landscape of immunogenic and immunodominant epitopes recognized by CD8+ T cells. Here, we analyze samples from 31 patients with COVID-19 for CD8+ T cell recognition of 500 peptide-HLA class I complexes, restricted by 10 common HLA alleles. We identify 18 CD8+ T cell recognized SARS-CoV-2 epitopes, including an epitope with immunodominant features derived from ORF1ab and restricted by HLA-A*01:01. In-depth characterization of SARS-CoV-2-specific CD8+ T cell responses of patients with acute critical and severe disease reveals high expression of NKG2A, lack of cytokine production and a gene expression profile inhibiting T cell re-activation and migration while sustaining survival. SARS-CoV-2-specific CD8+ T cell responses are detectable up to 5 months after recovery from critical and severe disease, and these responses convert from dysfunctional effector to functional memory CD8+ T cells during convalescence.

Many viral antigens have been identified in patients with COVID-19 patients, but which of these result in meaningful immune responses is unclear. Here the authors identify a range of SARS-CoV-2 CD8+ T cell responses across patients including a response targeting an epitope of ORF1ab with immunodominant properties.

Details

Title
Identification and characterization of a SARS-CoV-2 specific CD8+ T cell response with immunodominant features
Author
Gangaev Anastasia 1   VIAFID ORCID Logo  ; Ketelaars, Steven L, C 1 ; Isaeva, Olga I 1   VIAFID ORCID Logo  ; Patiwael Sanne 1 ; Dopler Anna 1   VIAFID ORCID Logo  ; Hoefakker Kelly 1 ; De Biasi Sara 2   VIAFID ORCID Logo  ; Gibellini Lara 2   VIAFID ORCID Logo  ; Mussini Cristina 2 ; Guaraldi Giovanni 2   VIAFID ORCID Logo  ; Girardis Massimo 2 ; Ormeno Cami M P Talavera 3 ; Hekking Paul J M 3 ; Lardy, Neubury M 4 ; Toebes Mireille 1 ; Balderas, Robert 5   VIAFID ORCID Logo  ; Schumacher, Ton N 1   VIAFID ORCID Logo  ; Ovaa Huib 3   VIAFID ORCID Logo  ; Cossarizza Andrea 2   VIAFID ORCID Logo  ; Kvistborg Pia 1   VIAFID ORCID Logo 

 The Netherlands Cancer Institute, Division of Molecular Oncology and Immunology, Amsterdam, The Netherlands (GRID:grid.430814.a) 
 University of Modena and Reggio Emilia School of Medicine, Modena, Italy (GRID:grid.7548.e) (ISNI:0000000121697570) 
 Leiden University Medical Center, Department of Cell and Chemical Biology, Leiden, The Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978) 
 Sanquin Diagnostics B.V., Department of Immunogenetics, Amsterdam, The Netherlands (GRID:grid.417732.4) (ISNI:0000 0001 2234 6887) 
 BD Biosciences, Department of Biological Sciences, San Jose, USA (GRID:grid.420052.1) (ISNI:0000 0004 0543 6807) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2524564917
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.